Quick Answer
LIPELLA PHARMACEUTICALS INC. reported Research And Development Expense of $3.61 million for the year ending 2024.
- LIPELLA PHARMACEUTICALS INC. showed an increase of +18.9% in Research And Development Expense from 2023 to 2024.
- This data is from LIPELLA PHARMACEUTICALS INC.'s annual report (Form 10-K), filed with the SEC on March 28, 2025.
- XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $676.0 thousand | Q2 2022: $742.7 thousand | Q3 2022: $651.0 thousand | Q1 2023: $693.7 thousand | Q2 2023: $1.06 million | Q3 2023: $833.3 thousand | Q1 2024: $842.6 thousand | Q2 2024: $661.6 thousand | Q3 2024: $1.05 million | Q1 2025: $993.5 thousand | Q2 2025: $791.6 thousand | Q3 2025: $721.0 thousand.
- Over the full 4 years of available data (2021 to 2024), LIPELLA PHARMACEUTICALS INC.'s Research And Development Expense has grown by 148.0%.
- Historical annual values: Fiscal year 2024: $3.61 million | Fiscal year 2023: $3.04 million | Fiscal year 2022: $2.55 million | Fiscal year 2021: $1.46 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: